AbdulazizAlomranMD

PubMed

• 53 citations
  Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.
  Rachel G. Casseres, Lisa Prussick, Pedro Zancanaro, Brooke E Rothstein, Deep Joshipura, Ami Saraiya, Shiu-chung Au, Abdulaziz Alomran, Rana Abdat, Minawaer Abudu, Cour...> ;Journal of the American Academy of Dermatology. 2020 Feb 7
• 60 citations
  Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-se...
  Lisa Prussick, Brooke E Rothstein, Deep Joshipura, A. Saraiya, Y. Turkowski, Rana Abdat, Abdulaziz Alomran, Pedro Zancanaro, Courtney Kachuk, Nicole Dumont, Alice B. G...> ;The British Journal of Dermatology. 2019 Sep 1
• 4 citations
  Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions.
  Lisa Prussick, Sarah Tonelli, Alice B. Gottlieb, Deep Joshipura, Abdulaziz Alomran, Pedro Zancanaro, RN Courtney Kachuk, Nicole Dumont, David Rosmarin> ;The Journal of Dermatological Treatment. 2019 Jun 24
• 44 citations
  Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B.
  Deep Joshipura, Abdulaziz Alomran, Pedro Zancanaro, David Rosmarin> ;Journal of the American Academy of Dermatology. 2018 Jun 1
• Join now to see all